Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 10, 2011

FDA clears Femasys low-pressure hysterosalpingography device

Femasys has received US Food and Drug Administration (FDA) clearance for its FemChec pressure management device, designed to deliver a low-pressure hysterosalpingography as a confirmation test following sterilisation surgery.

Femasys has received US Food and Drug Administration (FDA) clearance for its FemChec pressure management device, designed to deliver a low-pressure hysterosalpingography as a confirmation test following sterilisation surgery.

FemChec uses patent-pending technology that limits the applied intrauterine pressure to 200 mmHg, allowing physicians to meet the requirements of the mandatory hysterosalpingography confirmation test, while minimising improperly performed tests and procedure complications.

Femasys president and CEO Kathy Lee-Sepsick said the FemChec provides benefits to the physician and patient as a properly performed low-pressure confirmation test is critical to relying on the permanent sterilisation procedure long-term.

The company expects to market the first device in the US in December 2011.

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU